BioNTech Appoints Guido Oelkers Chief

BioNTech announced a leadership change on August 3, 2026. BioNTech’s Supervisory Board appointed Swedish Orphan Biovitrum CEO Guido Oelkers as Chief Executive Officer, succeeding co-founder Ugur Sahin, with Oelkers to take office by February 1, 2027, at the latest.

What changed

Guido Oelkers was named Chief Executive Officer. Oelkers succeeds BioNTech co-founder and Chief Executive Officer Ugur Sahin, who said he will be actively supporting Oelkers’ onboarding to ensure a smooth and successful handover.

Leader: Guido Oelkers
Role: Chief Executive Officer
Effective: By February 1, 2027, at the latest
Announcement date: August 3, 2026

Leadership background

Oelkers will join BioNTech from Swedish Orphan Biovitrum AB (Sobi), where he has served as CEO since 2017 and, according to BioNTech, more than quadrupled the company’s revenues over a nine-year period (financial years 2017 to 2026). Prior to joining Sobi he was CEO of BSN Medical Holding GmbH, President and CEO of Gambro AB, and CEO of Invida Holdings Pte. Ltd. BioNTech said he has over 30 years of experience in the biotechnology and pharmaceutical industries and holds a PhD in Business Management from Adelaide University, Australia.

The mandate

Oelkers said he is prioritizing BioNTech’s evolution into a global biopharmaceutical company with multiple approved products by 2030 while continuing to advance its pre-clinical and clinical portfolio in line with the company’s strategy. Supervisory Board Chairman Helmut Jeggle said the appointment would position the company well to deliver on its key objectives to become a multi-product company.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

BioNTech